These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 24692774)

  • 1. Evaluation of the effect of methylphenidate by computed tomography, electroencephalography, neuropsychological tests, and clinical symptoms in children with attention-deficit/hyperactivity disorder: A prospective cohort study.
    Yildiz Oc O; Agaoglu B; Sen Berk F; Komsuoglu S; Karakaya I; Coskun A
    Curr Ther Res Clin Exp; 2007 Nov; 68(6):432-49. PubMed ID: 24692774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term efficacy and tolerability of methylphenidate in children with traumatic brain injury and attention problems.
    Ekinci O; Direk MÇ; Gunes S; Teke H; Ekinci N; Yıldırım F; Okuyaz Ç
    Brain Dev; 2017 Apr; 39(4):327-336. PubMed ID: 27903419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from Methylphenidate-Immediate Release (MPH-IR) to Methylphenidate-OROS (OROS-MPH): A Multi-center, Open-label Study in Korea.
    Kim BN; Kim YN; Cheong US; Kim JW; Hwang JW; Shin MS; Cho SC;
    Clin Psychopharmacol Neurosci; 2011 Apr; 9(1):29-35. PubMed ID: 23430964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.
    Lam AP; Matthies S; Graf E; Colla M; Jacob C; Sobanski E; Alm B; Rösler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Müller HHO; Lücke C; Huss M; Jans T; Berger M; Tebartz van Elst L; Philipsen A;
    JAMA Netw Open; 2019 May; 2(5):e194980. PubMed ID: 31150084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
    CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The usefulness of Conners' Rating Scales-Revised in screening for attention deficit hyperactivity disorder in children with intellectual disabilities and borderline intelligence.
    Deb S; Dhaliwal AJ; Roy M
    J Intellect Disabil Res; 2008 Nov; 52(11):950-65. PubMed ID: 18179511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis.
    Jain R; Babcock T; Burtea T; Dirks B; Adeyi B; Scheckner B; Lasser R
    Child Adolesc Psychiatry Ment Health; 2011 Nov; 5(1):35. PubMed ID: 22054243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial.
    Efron D; Jarman F; Barker M
    Pediatrics; 1997 Dec; 100(6):E6. PubMed ID: 9382907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-term methylphenidate treatment: a pilot follow-up clinical and SPECT study.
    Akay AP; Kaya GC; Emiroğlu NI; Aydin A; Monkul ES; Taşçi C; Miral S; Durak H
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1219-24. PubMed ID: 16616981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of maternal symptom ratings and other clinical features on short-term treatment response to OROS methylphenidate in children and adolescents with ADHD in a naturalistic clinical setting.
    Tasgin EC; Oner O; Yurtbasi P; Munir K
    Klinik Psikofarmakol Bulteni; 2016; 26(2):126-133. PubMed ID: 27746700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
    Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Ferritin on Short-Term Treatment Response in Attention Deficit Hyperactivity Disorder.
    Oner P; Oner O; Cop E; Munir KM
    Klinik Psikofarmakol Bulteni; 2012; 22(4):325-331. PubMed ID: 28804252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we predict short-term side effects of methylphenidate immediate-release?
    Karabekiroglu K; Yazgan YM; Dedeoglu C
    Int J Psychiatry Clin Pract; 2008; 12(1):48-54. PubMed ID: 24916497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL
    J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903
    [No Abstract]   [Full Text] [Related]  

  • 18. The Effects of Methylphenidate Treatment on Bullying Perpetration and Victimization in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Karaosman T; Gumus YY
    J Child Adolesc Psychopharmacol; 2022 Mar; 32(2):107-116. PubMed ID: 35244454
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders.
    Ghuman JK; Aman MG; Lecavalier L; Riddle MA; Gelenberg A; Wright R; Rice S; Ghuman HS; Fort C
    J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):329-39. PubMed ID: 19702485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is contrast sensitivity a physiological marker in attention-deficit hyperactivity disorder?
    Dönmez YE; Özcan ÖÖ; Çankaya C; Berker M; Atas PBU; Güntürkün PN; Ceylan OM
    Med Hypotheses; 2020 Dec; 145():110326. PubMed ID: 33075582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.